Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...
The maintenance inhalers available for obstructive lung disease are long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs). We use all three ...
Findings support the most recent Global Initiative for Chronic Obstructive Lung Disease recommendations and the European Respiratory Society Task Force report on ICS withdrawal in COPD. The study ...
CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...
GSK expects that it respiratory sales in 2020 will be at atleast at the same levels as in 2015. Advair generic competition will knock off almost 50% of GSK's respiratory business by 2020. The much ...
Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...
(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...
SAN FRANCISCO -- Patients with chronic obstructive pulmonary disease (COPD) who changed treatment from so-called triple therapy to a two-drug product omitting the inhaled corticosteroid (ICS) ...
Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation strategies, said Sara Assaf, MD. There are significant long-term systemic risks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results